WASHINGTON—The Federal Trade Commission on Tuesday challenged Illumina Inc.’s. proposed acquisition of Pacific Biosciences of California, a $1.2 billion deal in the life-sciences industry.
The FTC is bringing an administrative lawsuit alleging the biotech acquisition would allow Illumina to unlawfully maintain a monopoly in next-generation DNA sequencing by eliminating PacBio as a nascent competitor.
हमने इस समाचार को संक्षेप में प्रस्तुत किया है ताकि आप इसे तुरंत पढ़ सकें। यदि आप समाचार में रुचि रखते हैं, तो आप पूरा पाठ यहां पढ़ सकते हैं। और पढो:
इंडिया ताज़ा खबर, इंडिया मुख्य बातें
Similar News:आप इससे मिलती-जुलती खबरें भी पढ़ सकते हैं जिन्हें हमने अन्य समाचार स्रोतों से एकत्र किया है।
Digital banking app MoneyLion is launching stock-trading in 2020 - Business InsiderMoneyLion, an online lending startup that raised over $200 million touting itself as an affordable banking option, is adding stock-trading in 2020
स्रोत: BusinessInsider - 🏆 729. / 51 और पढो »
DuPont chairman says deal with IFF gives new company 'double the R&D' of competitorsInternational Flavors & Fragrances is merging with DuPont's nutrition and biosciences unit, creating a $45.4 billion consumer goods giant. when do these CEO's lose their jobs for stocks which under perform greatly? $IFF stock been awful in a huge stock market year. Accountability is needed.
स्रोत: CNBC - 🏆 12. / 72 और पढो »